Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07513363

The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency

The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Overactive Bladder Avitaminosis Deficiency Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Lower Urinary Tract Symptoms Male Urogenital Diseases Malnutrition Nutrition Disorders Nutritional and Metabolic Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Urinary Bladder Diseases Urinary Bladder, Overactive Urogenital Diseases Urologic Diseases Urological Manifestations Vitamin D Deficiency

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Marmara University School of Medicine Urology Department

Pendik, Istanbul, 34100, Turkey (Türkiye)

Location contact

Cagri Akin Sekerci

CONTACT

[email protected]

05344525700

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency)

Exclusion criteria

  • Neurological diseases
  • Malignancy
  • Active urinary tract infections
  • Anatomical bladder anomalies
  • History of prior OAB treatment/urological surgery.

Treatment and study plan

urotherapy

Behavioral

Diagnosis and first-line treatment (urotherapy) will be conducted per European Association of Urology (EAU) guidelines.

Primary outcomes

  1. Changes in Urinary Biomarker Levels: * Quantitative measurement of urinary RhoA, NGF (Nerve Growth Factor), and BDNF (Brain-Derived Neurotrophic Factor) levels using the ELISA method.

    Time frame: One year

Secondary outcomes

  1. Clinical Symptom Improvement: * Reduction in LUTS (Lower Urinary Tract Symptoms) based on standardized voiding dysfunction symptom scores.

    Time frame: One year

Study contacts

Contact information is provided by the study sponsor or research team.

Hamza Tunahan Midilli

CONTACT

[email protected]

905449695848

Sponsors and collaborators

Lead sponsor

Tarik Emre Sener

Other

Registry information

Official study title

The Role of Urinary RhoA, NGF, and BDNF Levels in Diagnosis and Follow-up in Children With Overactive Bladder and Vitamin D Deficiency.

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Apr 7, 2026
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.